C100 (C100) Q1 2026 earnings summary

Executive summary

• Focused on strengthening operational structure and clarifying priorities to support long-term growth.

• Enhanced internal processes and organization to better capture business opportunities.

• Portfolio company Hunter Capital RTO 1 signed LOI for reverse merger with ResoTher Pharma, implying a combined valuation of 365–405 MSEK.

• Portfolio company Terranet signed a new evaluation agreement in the defense sector, expanding commercial applications.

Financial highlights

• Net sales for Q1 2026 were 0 SEK; EBITDA was -260 TSEK; net income after financial items was 235 TSEK.

• Earnings per share for Q1 2026 were 0.0018 SEK.

• Cash and cash equivalents as of March 31, 2026, were 1.33 MSEK; equity was 23.77 MSEK.

• Total assets as of March 31, 2026, were 28.35 MSEK; equity ratio was 84%.

• Depreciation for the quarter was -1.69 MSEK; patents valued at 14 MSEK.

Outlook and guidance

• Management expresses a positive outlook for the remainder of the year, citing a clearer direction and strengthened team.

• Liquidity is deemed sufficient for the next 12 months.